4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
To develop and investigate a novel radiotherapy technique for preserving lung function based on a map of lung function.
Checked against the public recordLast updated May 8, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- Billy W. Loo Jr.
- Interventions being studied
- Device: Real-time Position Management system; Device: Discovery ST multislice PET/CT scanner; Device: Infinia Hawkeye SPECT/CT gamma camera; Device: Pinnacle3 treatment planning system; Device: SKYLight nuclear camera; Drug: DTPA; Drug: TECHNETIUM TC 99M MAA
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Eligible disease(s)/stage(s) AJCC Stage I, II, III or IV lung cancer of any histology to be treated using radiotherapy will be eligible for this study. Note that we will carefully consider the inclusion of cases with turbulent flow or greater flow velocities (Cabahug et al., 1996; Crawford et al., 1990) and COPD cases (Magnant et al., 2006) due to the impaction of aerosol particles in central airways. * Allowable type and amount of prior therapy. Any types and amounts of prior therapy will be allowed for this study. * Age restriction and/or gender/ethnic restrictions * Patients must be greater than or equal to 18 years of age. * There are no gender or ethnic restrictions. * Life expectancy restrictions - None. * ECOG or Karnofsky Performance Status * Not employed. Note that patients will need to be sufficiently healthy to undergo audiovisual (AV) biofeedback to generate high quality 4D-CT images. * Requirements for organ and marrow function None. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Children (less than 18 years of age), pregnant women, Stanford employees or students, or prisoners will be excluded from this study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University School of MedicineStanford, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 8, 2017. Always confirm current availability with the study team.